
On December 22, 2024, someone told ByHeart that a baby was in the hospital with suspected botulism.
Nothing in the FDA’s records shows that ByHeart recalled anything, called California’s Infant Botulism Treatment and Prevention Program, or did anything at all except mark the complaint “lost to follow-up.”
Nearly eleven months later, on November 8, 2025, ByHeart recalled two lots. Three days after that, it recalled everything it had ever made.
I know this because the FDA has now released three inspection reports for BlendHouse Portland, the Oregon plant that filled every can and stick pack of ByHeart Whole Nutrition: April 2024, March 2025, and the amended report from the November 2025 outbreak inspection. Read them in order and you watch a complaint system fail in slow motion.
“Only Ever Received One”
When the FDA walked into Portland on November 11, 2025, on what it called a “mission critical” outbreak inspection, the plant’s Director of Quality told investigators the company had “only ever received one complaint” where a parent reported a hospitalization and suspected C. botulinum. Complaint CN-005563. (Outbreak EIR, p. 4.)
The complaint table gives the date: December 22, 2024. The parent was “lost to follow-up.” No lot number was ever obtained. That is the whole entry. (Outbreak EIR, pp. 7–8.)
Infant botulism is rare, roughly a hundred or so cases a year nationwide. Before 2025, no one had ever tied an outbreak of it to infant formula. A parent calling a formula company to say the doctors think my baby has botulism is not a colic complaint. It is a five-alarm fire.
And ByHeart’s own policy said so. Under the complaint procedure the FDA described, any health complaint involving hospitalization is a “serious” complaint, and ByHeart’s Chief Medical Officer is supposed to review every health complaint for “a potential for serious adverse health consequences.” (March 2025 EIR, p. 3.)
Three Months Later, the FDA Came Back and Never Heard About It
In March 2025, the FDA inspected the same Portland plant. The investigator reviewed ByHeart’s complaints from April 26, 2024 through March 14, 2025, a window that includes December 22, 2024.
Here is what ByHeart reported for that window: 3,247 complaints, 2,167 of them health-related. Of those 2,167, only 69 were forwarded to the Portland plant. Of those 69, ten were classified as “sensitive.” (March 2025 EIR, p. 4.)
The investigator then listed all ten, one by one. Every one was a bacterial illness. None was the December 22 botulism complaint. The word “botulism” does not appear anywhere in that 30-page report. (March 2025 EIR, pp. 4–7.)
The plant got “No Action Indicated.” (Food Safety News.)
So, one of two things happened. Either the December complaint never made it from ByHeart’s New York headquarters to the plant, or it made it and was not classified as sensitive. Either way, a hospitalized baby with suspected botulism did not make the list of complaints worth showing the FDA. Ten bacterial complaints did.
The Ten Sensitive Complaints
These are the complaints ByHeart did let the FDA see. Read them:
A daughter diagnosed with Salmonella. (24-003.)
An infant with “a salmonella infection that has entered the blood stream.” (24-011.)
A bad diaper rash and diarrhea, later diagnosed as Campylobacter. (24-035.)
An infant’s stool positive for Salmonella. (24-047.) Another. (24-059.)
An infant who “developed Salmonella poisoning” after drinking two batches. ByHeart opened two separate investigations, one per batch. (24-061 and 24-063.)
Mucous, diarrhea and blood, with cultures confirming Salmonella. (24-066.)
Two weeks of diarrhea, positive for E. coli. (24-080.)
Diarrhea, high fever, and blood and mucous in the stool, diagnosed as Salmonella. (24-0084.) (March 2025 EIR, pp. 4–6.)
That is eight Salmonella complaint files, one Campylobacter, one E. coli.
And every investigation ended the same way. “No evidence that the batch of infant formula was contaminated.” “All process controls were effective at managing any risks.” (March 2025 EIR, pp. 4–7.)
Here is the trick. ByHeart told the FDA it “did not receive more than one sensitive complaint for any batch.” (March 2025 EIR, p. 4.) Of course not. It counted batch by batch. When one sick baby drank two batches, that became two investigations of one complaint each. A system built that way will never see a pattern, because it never puts two sick babies on the same page.
Before That: Three “Serious” Complaints, All Called Allergies
Go back one more year. In April 2024, the FDA inspected Portland for the first time. Between July 31, 2023 and April 23, 2024, ByHeart reported just three “serious” health complaints. All three involved hospitalization. ByHeart called two of them milk protein allergies and one an allergy “not otherwise specified.” None of the complaints it sent the Portland plant in that period was health-related at all. (April 2024 EIR, pp. 3–4.)
Remember those dates. When CDC and FDA later looked backward, they found ByHeart botulism cases with onsets starting in December 2023, and California reported six more cases with onsets between November 2024 and June 2025. I have written about how this outbreak went on for years. Babies were getting sick during exactly the period when ByHeart’s complaint files showed nothing but allergies and, later, a botulism report closed as lost to follow-up.
What ByHeart Was Looking For
The March 2025 report also explains why ByHeart never found the organism. ByHeart’s food safety plan for Portland “did not identify any potential physical, chemical, or biological hazards” associated with the ingredients it received. (March 2025 EIR, p. 18.) The base powder, made with organic whole milk powder, was not treated as a hazard.
Its finished-product testing covered Cronobacter, Salmonella, Listeria, Staph aureus, E. coli and coliforms, Bacillus cereus, and aerobic plate count. Not C. botulinum. (March 2025 EIR, p. 19.) The outbreak report says the same thing about the two recalled lots: their release testing covered indicator organisms, Salmonella, and Cronobacter. (Outbreak EIR, p. 20.)
Even the Cronobacter protection did not work. ByHeart bought in-line equipment in 2022 “as an extra layer of protection against Cronobacter.” It never ran at its factory certification, and after troubleshooting from September 2023 to June 2025, ByHeart stopped counting it as a control. (Outbreak EIR, p. 20.)
The Constipation Complaints
Constipation is usually the first sign of infant botulism. The outbreak report lists what parents said about the two recalled lots:
A parent said ByHeart caused constipation, confirmed by a pediatrician. It went away when the baby came off ByHeart and came back when ByHeart was restarted. The FDA’s entry ends: “No root cause analysis was conducted.” (CN-007818.)
A colicky, constipated baby with a swollen belly. Lost to follow-up. (CN-007873.)
A ten-month-old constipated for four days. (CN-008241.) Another baby “getting constipated.” Three calls, lost to follow-up. (CN-008203.)
And an infant with no bowel movement for three weeks. ByHeart’s answer: it “did not receive similar complaints.” (193253.) (Outbreak EIR, pp. 4–8.)
Then the Botulism Complaints Came
After the recall, the complaints stopped being subtle. Two parents told the FDA their babies on ByHeart had infant botulism. (CN-008142, CN-008141.) A baby was hospitalized and tested for “GI bacteria including botulism” after four canisters from a recalled batch. (CN-008170.) And this, in full: “We are in the hospital with our daughter. She is being treated for botulism.” (CN-008192.) (Outbreak EIR, pp. 4–6.)
Many complaints the FDA forwarded were simply not in ByHeart’s system, or got “no response or follow up without a valid lot code.” For one family, Portland’s quality director “was not sure why” no one followed up, and ByHeart opened a deviation report to explain it. (Outbreak EIR, pp. 8–9.)
Who Was Responsible
The outbreak report names Ron Belldegrun, ByHeart’s CEO and owner, as the company’s “most responsible person.” (Outbreak EIR, pp. 10, 15.) The same executives keep appearing at close-out: the Chief Quality Officer, the head of supply chain, the VP of Quality, and the senior director of manufacturing sat in on March 2025 (March 2025 EIR, pp. 26–27), and again in January 2026, joined by the Chief Medical Officer. (Outbreak EIR, p. 27.) In March 2025 the FDA even reminded ByHeart that it was required to have a redundancy risk management plan. (March 2025 EIR, p. 27.)
What Should Have Happened
I have done this work for more than thirty years. When a parent reports a hospitalized baby with suspected botulism, a responsible formula company calls back until it reaches the family. It calls the hospital. It calls California’s Infant Botulism program, which talks to every treating doctor in the country. It pulls its retains and sends them to a lab that can find C. botulinum. And it tells the FDA, and it puts that complaint in front of the next FDA investigator who walks in the door.
ByHeart wrote “lost to follow-up.” Three months later it showed the FDA ten bacterial complaints, each closed one batch at a time. Nearly a year later, 48 babies in 17 states had been hospitalized and treated with BabyBIG.
Complaint systems exist for one reason: to hear the warning before the outbreak. ByHeart heard it. It just was not listening.
Sources










